BMS cut its 2017 guidance, but its I-O franchise remains strong—and one analyst suggests setbacks plus value could tag the company as a takeover target.

It took months, but growth-starved Johnson & Johnson and longtime solo flyer Actelion finally have a deal that’ll make both parties happy.

Could Actelion's $26 billion-plus deal talks with J&J fall through, now that its PAH drug Opsumit has fallen short in a study designed to grow its…

Sanofi’s Olivier Brandicourt has said acquisitions will help the French drugmaker grow, but the CEO has been unable to pull off a major deal.

Bayer’s $66 billion Monsanto takeover has plenty of critics. But thanks to an $8 billion R&D pledge, it has one key backer: U.S. President-elect Donald…

Johnson & Johnson and Actelion reportedly have settled a key condition of their long-discussed transaction: price.

On New Year’s Day, Sanofi and Boehringer Ingelheim closed a $12.5 billion asset swap that had been in the works for a year, giving the closely held Germany-…

Deal talk is pretty hard to ignore at the J.P. Morgan Healthcare Conference—especially for a pair of the world’s biggest hemophilia drugmakers.

Headlines continue to roll out of the J.P. Morgan conference in what may be the busiest year yet for news at the not-to-miss meeting. Here are our latest CEO…

M&A